scholarly journals PRIMARY MULTIDRUG RESISTANT TUBERCULOSIS (MDR‐TB) AMONG TYPE‐2 DIABETES MELLITUS (DM) PATIENT: CASE SERIES

Respirology ◽  
2019 ◽  
Vol 24 (S2) ◽  
pp. 156-156
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Case Series ◽  
Multidrug Resistant ◽  
Patient Case ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Mdr Tb

scholarly journals Proportion of Rifampicin Resistance in Sputum Smear Positive Pulmonary Tuberculosis with Diabetes Mellitus in Urban Bengaluru - A Cross-Sectional Study

2021 ◽  
Vol 8 (23) ◽  
pp. 1888-1893
Author(s):  
Srinivasa Kaligonahalli Venkataramanappa ◽  
Jeevan Basavaraj
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Pulmonary Tuberculosis ◽  
Multidrug Resistant ◽  
Rifampicin Resistance ◽  
Sputum Smear ◽  
Diabetic Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis

BACKGROUND Pulmonary tuberculosis (PTB) still remains a global public health problem. Diabetes along with poor glycaemic control leads to an immune compromised state. Type 2 diabetes (DM) is a strong risk factor for tuberculosis (TB) and is associated with a slower response to TB treatment and a higher mortality rate. Objective of the study was to determine the prevalence of rifampicin resistance in pulmonary tuberculosis in patients with DM. METHODS The study was conducted in General Medicine Department, Dr. B.R. Ambedkar Medical College, Bengaluru, Karnataka, from July 2018 to December 2019. Sputum was collected from a total of 100 patients who were sputum smear positive for acid fast bacilli (AFB). Sample was collected and was subjected to GeneXpert testing for the evaluation of resistance against rifampicin. RESULTS In our study the incidence of rifampicin resistance was 45.16 % in diabetes and 5.79 % in non-diabetes which was statistically significant ( 2 -1.1; p-0.01) between rifampicin resistance and diabetic patients’ status with active TB in South Karnataka, India. This result supports previous research showing a higher multidrug-resistant tuberculosis risk in tuberculosis & diabetes patients relative to those with no diabetes. Additionally, correlation of other findings between type 2 diabetes & multidrug-resistant tuberculosis as well as delayed time to sputum smear conversion were confirmed. CONCLUSIONS The results showed correlation between diabetes & rifampicin resistance and probably suggest the necessity of integrated diabetes and tuberculosis surveillance programs in South Karnataka, India. KEYWORDS Rifampicin, Tuberculosis, Diabetes Mellitus

scholarly journals Significance of the Differential Peptidome in Multidrug-Resistant Tuberculosis

2019 ◽  
Vol 2019 ◽  
pp. 1-12
Author(s):  
Yan Yang ◽  
Jianqing Wu
Keyword(s):  
Multidrug Resistant ◽  
Fold Change ◽  
Differentially Expressed ◽  
Coagulation System ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Precursor Proteins ◽  
Canonical Pathways ◽  
Mdr Tb

Most multidrug-resistant tuberculosis (MDR-TB) patients fail to receive a timely diagnosis and treatment. Therefore, we explored the differentially expressed peptides in MDR-TB compared with drug-susceptible tuberculosis (DS-TB) patients using LC-MS/MS and Ingenuity Pathway Analysis (IPA) to analyse the potential significance of these differentially expressed peptides. A total of 301 peptides were differentially expressed between MDR-TB and DS-TB groups. Of these, 24 and 16 peptides exhibited presented high (fold change ≥ 2.0, P < 0.05) and low (fold change ≤ −2.0, P < 0.05) levels in MDR-TB. Significant canonical pathways included the prothrombin activation system, coagulation system, and complement system. In the network of differentially expressed precursor proteins, lipopolysaccharide (LPS) regulates many precursor proteins, including four proteins correlated with organism survival. These four important differentially expressed proteins are prothrombin (F2), complement receptor type 2 (CR2), collagen alpha-2(V) chain (COL5A2), and inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4). After addition of CR2 peptide, IL-6 mRNA expression in THP-1 cells decreased significantly in dose- and time-dependent manners. Cumulatively, our study proposes potential biomarkers for MDR-TB diagnosis and enables a better understanding of the pathogenesis of MDR-TB. The functions of differentially expressed peptides, especially CR2, in MDR-TB require further investigation.

scholarly journals Prevalence of Type 2 Diabetes Mellitus in Hepatitis C Virus Infected Population: A Southeast Asian Study

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Muhammad Sadik Memon ◽  
Zain Islam Arain ◽  
Farukh Naz ◽  
Madiha Zaki ◽  
Suresh Kumar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Demographic Data ◽  
Fasting Blood Glucose ◽  
Case Series ◽  
University Hospital

Purpose. The study was aimed to investigate the frequency of diabetes mellitus type 2 in patients infected with chronic hepatitis C virus and its association with cirrhosis.Patients and Methods. This prospective case series was conducted at Section of Gastroenterology and Hepatology, Isra University Hospital, Hyderabad, over a period of 4 months from June 2009 to October 2009. Hepatitis C virus seropositive patients who were older than 18 years, diabetic or nondiabetic, were included. Basic demographic data collected by questionnaire and laboratory investigations including fasting blood glucose levels, serum cholesterol, and liver function tests were done. A logistic regression model was used to explore the association between diabetic and nondiabetic HCV seropositives and type 2 diabetes mellitus with cirrhosis.Results. A total of 361 patients with hepatitis C were analyzed; the prevalence of type 2 diabetes mellitus in HCV patients was 31.5%. Out of the total number of the participants, 58.4% (n= 211) were cirrhotics, while 41.6% (n= 150) were noncirrhotic HCV seropositives. In multivariate analysis, cirrhotic patients appeared significantly more likely (P= 0.01) to be diabetic as compared with noncirrhotic patients (OR = 2.005, 95% CI: 1.15, 3.43).Conclusion. Advancing age, increased weight, and HCV genotype 3 are independent predictors of type 2 diabetes in HCV seropositive patients, and there is a statistically significant association of cirrhosis observed with type 2 diabetes mellitus.

scholarly journals Analysis of Smear Microscopy and Culture Conversion Results in Multidrug-Resistant Tuberculosis Patients with and without Type 2 Diabetes Mellitus

2020 ◽  
Vol 26 (3) ◽  
Author(s):  
Henny Fauziah ◽  
Aprianti S. ◽  
Handayani I. ◽  
Kadir NA
Keyword(s):  
Diabetes Mellitus ◽  
Multidrug Resistant ◽  
World Health ◽  
Smear Microscopy ◽  
Tuberculosis Patients ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Significant Difference ◽  
Mdr Tb ◽  
Culture Conversion

  The World Health Organization (WHO) recommended microscopic AFB smear examination and culture as follow-ups to the response of MDR TB therapy. Analyzed the results of microscopic AFB smear and culture conversion as well as treatment outcome in Multidrug-Resistant Tuberculosis (MDR-TB) patients with and without Diabetes Mellitus (DM). This is a retrospective study involved 70 MDR-TB patients with (27 patients) with DM and without DM (43 patients) who had microscopic AFB smear and culture results at the start of the follow-up therapy. This research was conducted at Labuang Baji Regional Public Hospital, Makassar, from June to July 2019, used medical records of MDR-TB patients the period of June 2016 to December 2017. The results showed that 52 out of 70 MDR-TB patients had microscopic AFB smear and culture conversion in MDR-TB with DM (21 patients) and without DM (31 patients). The duration of microscopic AFB smear conversion in MDR TB patients with DM (3.33±0.54 months) was longer than patients without DM (2.07±0.05 months), p=0.001. While in culture conversion, there was no significant difference between MDR-TB with DM (1.28±0.64 months) and without DM (1.25±0.59), p=0.648. The recovery outcome between MDR-TB with (48.1%) and without DM (48.8%) was not significantly different. However, the output of treatment failure was greater in DM (11.2%) than without DM (2.3%), although statistically, there was no significant difference (p=0.568). Multidrug-resistant tuberculosis patients with DM experienced slower microscopic AFB smear conversion than MDR-TB patients without DM. However, in culture, there was no significant difference in the conversion period between the two groups. MDR-TB patients, both of with and without DM, had the same chance of recovery.

scholarly journals Metformin use in patients with type 2 diabetes mellitus and chronic kidney disease: An evidence-based review

2021 ◽  
Vol 50 (2) ◽  
pp. 159-170
Author(s):  
Felicia Clara JH Tan ◽  
Seng Bin Ang ◽  
Yong Mong Bee
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lactic Acidosis ◽  
Cohort Studies ◽  
Case Series ◽  
Stage 4 ◽  
Ckd Stage ◽  
All Cause Mortality

Introduction: Practice guidelines advise caution on the use of metformin in patients with type 2 diabetes mellitus with chronic kidney disease (CKD). This review aims to examine the evidence for the benefits and risks of metformin use in patients with T2DM and CKD. Methods: The Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials and PubMed were searched; the references of selected papers were hand searched. Systematic reviews, randomised controlled trials, cohort studies, case series and case-control studies were included. The full text of selected articles was reviewed. The outcomes studied were all-cause mortality, cardiovascular complications, lactic acidosis and worsening of renal function. Recommendations were graded according to the Scottish Intercollegiate Guidelines Network system. Results: A total of 139 unique articles were identified, 14 of which met the inclusion criteria and were selected for full-text review. Four cohort studies reported an association between metformin use and improved all-cause mortality in CKD stage 4 and better. Two cohort studies reported improved cardiovascular outcomes with metformin use. Four cohort studies, 1 case series and 1 case-control study reported no significant association between metformin use and an increased risk of lactic acidosis in CKD. There is a moderate level of evidence to support reduced mortality, improved cardiovascular outcomes and a low risk of lactic acidosis with metformin use in patients with T2DM and with CKD stage 4 and above. Conclusion: Existing recommendations to restrict metformin use in diabetes patients with CKD need to be reviewed in light of emerging evidence supporting its overall benefits in these patients. Keywords: Chronic renal insufficiency, metformin, type 2 diabetes mellitus

scholarly journals RISK FACTORS FOR DEVELOPMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG RELAPSED PATIENTS IN WEST PAPUA, INDONESIA: A DESCRIPTIVE AND ANALYTICAL STUDY

2019 ◽  
pp. 50-55
Author(s):  
MOHAMMAD A. WIJAYANTO ◽  
RAIHAN A. ARNANDA ◽  
EDO P. THAMRIN
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Multidrug Resistant ◽  
Smoking History ◽  
Bivariate Analysis ◽  
Control Group ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
West Papua ◽  
Mdr Tb

Objective: Indonesia has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB), with 6800 new cases of MDR-TB annually and a previously reported cure rate of 51%. This study aimed to identify the risk factors that affect the development of MDR-TB in the diverse population of West Papua. Methods: A case–control study was conducted in Sorong Regency Regional Hospital, a referral center for MDR-TB in West Papua. Data were obtained from medical records of patients with relapsed TB between January 2014 and September 2017. Extracted data included demographic characteristics, family history, medication history (type of medication and duration), smoking history, supporting examinations (sputum test for acid-fast bacilli [AFB] and radiologist interpretation of thoracic X-ray), and comorbidities (HIV and diabetes mellitus). Results: Among 549 patients with suspected MDR-TB, 45 were confirmed to have MDR-TB. These 45 patients were defined as the case group and compared with a control group of 45 relapsed patients who had drug-sensitive TB. A great number of subjects in both case and control groups (44.4% and 57.8%) were categorized as previously lost to follow-up. Bivariate analysis using the chi-squared test found that an AFB result of+3 (odds ratio [OR]: 5.33, 95% confidence interval [CI] 1.76–16.09), diabetes mellitus (OR: 6.14, 95% CI 1.26–29.89), and completion of intensive-phase category I anti-TB therapy (OR: 3.25, 95% CI 1.04–10.07) were associated with MDR-TB. Conclusion: These clinical variables provide initial information about MDR-TB in West Papua and will assist clinicians to manage patients in related populations who have these risk factors.

scholarly journals DKA in patients with pre-existing type 2 diabetes mellitus related to COVID-19: a case series

2021 ◽  
Vol 2021 ◽  
Author(s):  
Anthony Ramos-Yataco ◽  
Kelly Meza ◽  
Reyna Cecilia Farfán-García ◽  
Solange Ortega-Rojas ◽  
Isaac Salinas-Mamani ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Case Series ◽  
Blood Analysis ◽  
List Type ◽  
Metabolic Complications ◽  
Arterial Blood ◽  
First Case

Summary The first case of the novel coronavirus infection (COVID-19) in Peru was reported on March 6, 2020. As of September 7, 2020, about 700 000 cases of COVID-19 resulting in 29,976 deaths have been confirmed by the Ministry of Health. Among COVID-19 patients with co-morbidities, type 2 diabetes mellitus (T2DM) has been recognized as a risk factor for severe disease. Patients with T2DM may experience diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic (HHS) if infected with the coronavirus 2 (SARS-CoV-2). Regular blood analysis including arterial blood gas is essential in monitoring the care of patients with T2DM infected with COVID-19. We report five cases of DKA in patients with underlying T2DM that presented with severe COVID-19 infection. Learning points COVID-19 may cause acute metabolic dysregulations in patients with T2DM. It is important to monitor basic metabolic panel (BMP) and arterial blood gases (ABGs) in patients with COVID-19 since metabolic complications can develop unexpectedly. Patients with T2DM develop an inflammatory syndrome characterized by severe insulin resistance and B cell dysfunction that can lead to DKA.

Functional medicine and chiropractic: A case series in Type 2 Diabetes Mellitus reversal

2011 ◽  
Vol 14 (4) ◽  
pp. 147-148 ◽  
Author(s):  
Stephanie Chaney ◽  
Tom Chaney ◽  
Paul A. Oakley
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Case Series
Sign in / Sign up

Export Citation Format

Share Document